Related Experiment Video
Updated: Apr 26, 2026
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
Efficacy of motesanib diphosphate in non-small-cell lung cancer
Erika Rijavec1, Carlo Genova, Giulia Barletta
1IRCCS AOU San Martino IST - Istituto Nazionale per la Ricerca sul Cancro, UOS Tumori Polmonari , Largo Rosanna Benzi No 10, 16132 Genova , Italy +39 0105600665 ; +39 0105600795 ; ery80x@yahoo.it.
Introduction:
Angiogenesis plays a crucial role in the proliferation and in the metastatic spread of tumour cells. Several agents with anti-angiogenic activity have been tested in advanced non-small-cell lung cancer (NSCLC) patients. Motesanib (AMG 706) is a promising anti-angiogenic multi-targeted tyrosine kinase inhibitor (TKI), which has been investigated as a monotherapy or in combination with chemotherapy, in several types of cancer.
Areas Covered:
We have reviewed the literature, and we have presented the results of clinical trials that have investigated the administration of motesanib in advanced NSCLC patients.
Expert Opinion:
Encouraging results have been described with the administration of motesanib as first-line treatment in combination with carboplatin and paclitaxel in Asian patients with non-squamous advanced NSCLC. Further studies are needed in order to identify the predictive biomarkers of response and to select patients who may benefit from this anti-angiogenic treatment.
Insights
Motesanib shows promise in treating advanced non-small-cell lung cancer (NSCLC). Combination therapy with motesanib, carboplatin, and paclitaxel yielded encouraging results in Asian patients with non-squamous NSCLC.
Area of Science:
- Oncology
- Pharmacology
Background:
- Angiogenesis is vital for tumor growth and metastasis.
- Anti-angiogenic agents are explored for advanced non-small-cell lung cancer (NSCLC).
- Motesanib (AMG 706) is a multi-targeted tyrosine kinase inhibitor (TKI) with anti-angiogenic properties.
Purpose of the Study:
- To review and present clinical trial data on motesanib in advanced NSCLC patients.
Main Methods:
- Literature review of clinical trials.
- Analysis of motesanib administration in advanced NSCLC.
Main Results:
- Motesanib, combined with carboplatin and paclitaxel, showed encouraging results as first-line treatment.
- Positive outcomes were observed in Asian patients with non-squamous advanced NSCLC.
Conclusions:
- Motesanib combination therapy demonstrates potential in specific NSCLC patient populations.
- Further research is required to identify predictive biomarkers for patient selection and optimize anti-angiogenic treatment strategies.
